Polycystic ovary syndrome (PCOS)
Conditions
Interventions
PCOS berberine treatment group:berberine treatment
PCOS control group:Blank control
Sponsors
Obstetris & Gynecology Hospital of Fudan University
Eligibility
Sex/Gender
Female
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1.Women aged 20–35 years; 2.BMI:18.5=BMI<30.0kg/m2; 3.The diagnosis of PCOS is in accordance with the Rotterdam criteria; 4.Written informed consent was obtained from all subjects;
Exclusion criteria
Exclusion criteria: 1.Patients with a confirmed allergy to the ingredients of the study medication, or who cannot tolerate the therapy; 2.Patients with reproductive, endocrine, metabolic, or immune system diseases that may significantly affect the evaluation of drug efficacy; 3.Patients with severe underlying diseases including cardiovascular, cerebrovascular, hepatic, renal insufficiency, or disorders of hematopoietic and coagulation systems; 4.Patients who have received other Chinese or Western medicines or health products for improving polycystic ovary syndrome within 14 days prior to screening, or who refuse to discontinue these medications during the trial; 5.Patients with abnormal liver and renal function during the screening period; 6.Patients deemed ineligible by the investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pro-inflammatory monocytes;Carotid Intima-Media Thickness; | — |
Countries
China
Contacts
Public ContactGao Ling
Obstetris & Gynecology Hospital of Fudan University
Outcome results
None listed